Academic MOUs
| MOU No. | Purpose | Parties | FDA Lead Center or Office/Contact | Effective Date | Expiration Date | Last Revision Date |
|---|---|---|---|---|---|---|
| 225-26-003 | This MOU outlines the framework for University of Guelph’s participation as a member of Vet-LIRN, a network of veterinary diagnostic laboratories that supports the documentation, investigation, and diagnosis of animal feed or drug related illnesses. | University of Guelph | Center for Veterinary Medicine (CVM) Dr. Gregory Tyson | 2026-01-28 | 2031-01-28 | |
| 225-25-011 | To share interests in promoting scientific progress through knowledge exchange of scientific capital in Clinical Pharmacology and translational research with a view to optimizing drug dosing and safety, focusing on public health. | Flinders University, College of Medicine and Public Health | Shiew-Mei Huang, Ph.D. Deputy Director Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) | 2025-09-30 | 2028-09-30 | |
| 225-24-007 | MOU establishes the terms for collaborative engagement between FDA and UCLA, as well as describe activities which can be pursued through a variety of programs, including but not limited to: (a) joint research projects in fields of mutual interest (b) exchange of academic publications and reports; (c) sharing of experiences in innovative teaching methods and course design; (d) organization of joint symposia, workshops, and conferences; (e) opportunities for faculty development and exchange; (f) opportunities for student exchange; and (g) opportunities for exchange of visiting research scholars. | University of California, Los Angeles (UCLA) | Padmaja Mummaneni, Ph.D. Senior Pharmacokineticsist/ Pharmacogeneticist, Division of Translational and Precision Medicine (DTPM), Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) | 2025-10-22 | 2030-10-22 | |
| 225-25-009 | MOU between FDA and The University of Manchester forms the basis for the development of scientific collaborations, outreach and educational initiatives, as well as intellectual partnerships to promote scientific progress through knowledge exchange of scientific capital in clinical pharmacology and translational research towards optimize drug dosing and to create algorithms to help with stratified medicines based on patient attributes. | University of Manchester, School of Health Sciences, Centre for Applied Pharmacokinetic Research | Shiew-Mei Huang, Ph.D. Deputy Director Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation and Research (CDER) | 2025-09-24 | 2028-09-24 | |
| 225-25-014 | Dartmouth and FDA/CDRH share interests in promoting scientific progress and translating innovation and scientific discoveries into practice in the areas of health and medicine. | Dartmouth College, Geisel School of Medicine | Brittany Caldwell, Ph.D., M.B.A. Director, Division of Partnerships and Innovation (DPI) | 2025-09-12 | 2030-09-12 | |
| 225-24-011 | This MOU outlines the framework for Tuskegee University’s participation as a member of Vet-LIRN, a network of veterinary diagnostic laboratories that supports the documentation, investigation, and diagnosis of animal feed or drug related illnesses. | Tuskegee University, College of Veterinary Medicine's Veterinary Diagnostic Services Laboratories (TUDSLs) | Center for Veterinary Medicine (CVM) Dr. Gregory Tyson | 2025-07-25 | 2030-07-25 | |
| 225-25-010 | This MOU outlines the framework for Texas A&M’s AgriLife participation as a member of Vet-LIRN, a network of veterinary diagnostic laboratories that supports the documentation, investigation, and diagnosis of animal feed or drug related illnesses. This memorandum supersedes MOU 225-20-004, dated May 8, 2020 | Texas A&M AgriLife Research (AgriLife) | Center for Veterinary Medicine (CVM) Dr. Gregory Tyson | 2025-06-30 | 2030-06-30 | |
| 225-25-007 | This MOU outlines the framework for University of Pennsylvania’s participation as a member of Vet-LIRN, a network of veterinary diagnostic laboratories that supports the documentation, investigation, and diagnosis of animal feed or drug related illnesses. | The Trustees of the University of Pennsylvania on behalf of the University of Pennsylvania School of Veterinary Medicine (Penn) | Center for Veterinary Medicine (CVM) Dr. Gregory Tyson | 2025-06-30 | 2030-06-30 | |
| 225-24-006 | This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | University of California San Francisco (UCSF) | Padmaja Mummaneni, PhD. Office of Translational Sciences (OTS) | 2024-03-11 | 2029-03-11 | |
| 225-24-003 | This MOU documents affiliation among Walter Reed, Uniformed Services University, and FDA in the established Clinical Pharmacology Fellowship Training Program. | Walter Reed, Uniformed Services University, and FDA | Padmaja Mummaneni, PhD. Office of Translational Sciences (OTS) | 2024-02-05 | 2032-07-01 | |
| 225-23-010 | Establishes the FDA-ASA Oncology Educational Fellowship. Both parties share interests in promoting scientific progress through exchange of scientific knowledge in statistical methods for clinical research, oncology education, collaborative learning, and research. | American Statistical Association (ASA) | Oncology Center of Excellence (OCE) Jennifer Gao M.D. Associate Director for Education 10903 New Hampshire Ave, WO 22/2135 Silver Spring, MD 20993 Jennifer.gao@fda.hhs.gov 240-402-4683 | 2023-06-06 | 2028-09-30 | |
| 225-23-007 | This MOU establishes the terms for collaboration to promote FDA and MSU’s shared interests, which can be pursued through a variety of programs. | Michigan State University (MSU) | CDER Padmaja Mummaneni, PhD (301) 796-2027 | 2023-08-01 | 2028-08-01 | 2023-08-01 |
| 225-23-002 | This MOU forms the basis for development of scientific collaborations, outreach and educational initiatives and intellectual partnerships between FDA and University of Pennsylvania, Perelman School of Medicine. | Perelman School of Medicine at the University of Pennsylvania (Penn Med) | Padmaja Mummaneni, Ph.D. Consumer Safety Officer, Regulatory Health Project Manager Center for Drug Evaluation and Research (CDER), Office of Translational Sciences, Office of Clinical Pharmacology 301-796-2027 | 2023-05-30 | 2028-05-30 | |
| 225-20-001 | Maryland Montgomery County Public Schools, collaboration to foster Scientific Technology Engineering and Math studies and career paths, along with educating youth about the dangers of opioid misuse and prevention of substance abuse. | Maryland, Montgomery Count Public school system | CDER Chekesha Clingman (301) 796-8531 | 2020-02-12 | 2025-02-12 | |
| 225-93-2001 | IL Inst. Tech., participation in short courses, workshops, & training programs in food safety and technology. | Illinois Institute of Technology | CFSAN Don Zink (240) 402-1693 | 1993-09-03 | Indefinite | |
| 225-02-8001 | Establishes terms of collaboration between FDA and UMD to support shared interest in scientific progress through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships. | University of Maryland | OC Eileen Parish (301) 796-8522 | 2002-09-04 | Indefinite | |
| 225-03-6000 | Establishes terms of collaboration between FDA and VA Polytechnic Institute to support shared interest in scientific progress through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships. | University of Houston | CDRH Michelle Chenault (240) 276-3815 | 2003-03-29 | Indefinite | |
| 225-03-8002 | Establishes terms of collaboration between FDA and VA Polytechnic Institute to support shared interest in scientific progress through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships. | Virginia Polytechnic Institute | OC Eileen Parish (301) 796-8522 | 2003-03-13 | Indefinite | |
| 225-03-8003 | Establishes terms of collaboration between FDA and Howard University to support shared interest in scientific progress affecting human and animal health and medicine through a variety of programs such as sabbaticals, postdoctoral fellowships, and student internships. | Howard University | OC Eileen Parish (301) 796-8522 | 2003-05-29 | Indefinite | |
| 225-05-6000 | To establish terms of collaboration between FDA and BWH to support shared interests and to begin the initiative "The FDA Brigham Elective Program for Residents in the Department of Medicine." | Brigham and Women's Hospital | CDRH Anindita Saha (301) 796-2537 Mimi Nguyen (301) 796-4125 | 2006-05-09 | Indefinite | |
| 225-05-6001 | Establishes collaboration between FDA, Duke University, and Duke University Health System, Inc. in sharing scientific information. | Duke University and Duke University Health System, Inc. | CDRH Annindita Saha (301) 796-2537 Mimi Nguyen 301-796-4125 | 2006-09-18 | Indefinite | |
| 225-07-6001 | Establishes the terms for collaborative research between the FDA and Stanford University to promote scientific progress in animal and human medicine. Amended to change POC and termination date. | Stanford University | CDRH Anindita Saha (301-796-2537 Mimi Nguyen 301-796-4125 | 2012-07-12 Revised on 2016-05-11 | Indefinite | |
| 225-07-8005 | To establish terms of collaboration between FDA and Duke, as a part of FDA's Critical Path Initiative. This MOU will serve as the basis of a Public Private Partnership hosted by Duke to systematically modernize the clinical trial process. | Duke University | OC Melissa Robb (301) 827-1516 | 2007-09-22 | Indefinite | |
| 225-07-8008-1 | To establish collaboration in the areas of advanced scientific training, information exchange and stimulation of cooperative research activities in biotechnology, bioethics, and nanotechnology, particularly with the Institute of NanoBioTechnology. Replaced MOU #s 225-07-8008 and 225-02-8000. | John Hopkins University | OC Eileen Parish (301) 796-8522 | 2015-05-20 | 2020-05-20 | |
| 225-07-8405 | Forms the basis for development of scientific collaborations, outreach and educational initiatives and intellectual partnerships between FDA and USM. | University System of Maryland | Office of the Chief Scientist | 2018-04-02 | Indefinite | |
| 225-11-0024 | Establishes a collaborative framework between the FDA and the University of Florida through a variety of programs, including collaborative education and research. Term Extension Modification. | University of Florida | CDER Ryan Chatman (301) 796-2106 | 2011-09-21 | 2021-09-19 | |
| 225-12-0004 | Establishes the collaboration between The United States Food and Drug Administration (FDA) and Thomas Jefferson University to share interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research Program. Time Extension Amendment | The Thomas Jefferson University | CDER Ryan Chatman (301) 796-2106 | 2011-12-09 | 2021-12-09 | |
| 225-12-0011 | Forms the basis for the initial relations between FDA and the University of Hawaii, College of Pharmacy for sabbaticals, research and scientific education | University of Hawaii Hilo, College of Pharmacy | OMH Richardae Araojo (301) 796-8000 | 2012-03-30 | Indefinite | |
| 225-12-0012 | Forms the basis for the initial relations between FDA and the University of Hawaii for sabbaticals, research and scientific education. | University of Hawaii at Manoa, Office of Public Health Studies | OMH Richardae Araojo (301) 796-8000 | 2012-04-24 | Indefinite | |
| 225-12-0018 | Establishes the terms between the Food and Drug Administration (FDA) and Stanford University (Stanford) to promote scientific progress through exchange of scientific capital in diverse fields of science that affect human and animal health and medicine. | Stanford University | CDER Gerald J. Dal Pan, MD, MHS 301-796-2380 | 2012-05-17 | Indefinite | |
| 225-12-0029 | Forms the basis for the initial relations between FDA and Meharry Medical College (Meharry) for sabbaticals, research and scientific education. | Meharry Medical College | OMH Richardae Araojo (301) 796-8000 | 2012-06-21 | Indefinite | |
| 225-13-002 | This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | Harvard T.H. Chan School of Public Health | CDER Scott N. Goldie General Health Scientist (301) 796-2055 | 2018-01-18 | 2021-01-18 | |
| 225-13-0025 | Establishes terms of collaboration between FDA and the University of Hamburg for development of scientific collaborations, outreach and educational initiatives, and intellectual partnerships. | University of Hamburg | CFSAN Eric Brown, PhD (240) 402-2020 | 2013-09-05 | Indefinite | |
| 225-14-007 | This Memorandum of Understanding (MOU) states the mutual intention of the parties to seek opportunities for collaboration and to promote shared interests in various science-based academic initiatives, fellowships, and student internships. | York College of the City University of New York | OMH Richardae Araojo (301) 796-8000 | 2014-02-20 | Indefinite | |
| 225-15-006 | Collaboration to promote these shared interests, which can be pursued through information sharing in regulatory science research, training, sabbaticals, postdoctoral fellowships, and student internships. | Morehouse School of Medicine | OMH Richardae Araojo (301) 796-8000 | 2014-12-22 | Indefinite | |
| 225-15-013 | Shared interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research Programs. This was amended to extend the termination date to June 30, 2021. | University of California at San Diego | CDER | 2012-06-30 Revised on: 2018-05-08, 2021-08-06 | 2026-08-06 | |
| 225-16-001 | Identify indicators of cardiovascular risk, predict adverse cardiovascular events associated with therapeutic interventions, and improve the clinical utility of biomarker technologies as diagnostic and assessment tools that facilitate developing safer and more effective cardiovascular therapies, diagnostic and assessment tools. | Duke University Cardiac Safety Research Consortium | Norman Stockbridge, MD, PhD (301) 796-9841 | 2015-10-28 | Indefinite | |
| 225-16-005 | Establish opportunities for scientific and medical exchange between the FDA scientific staff and the University’s science students and academicians through collaborative research and training. | University of Rochester | OCS Eileen Parish, M.D. (301) 796-8522 | 2015-12-14 | 2020-12-14 | |
| 225-16-006 | To establish a mutually acceptable agreement between FDA and Cornell that will provide for collaboration on the development and delivery of training to FDA and State, Local, Tribal, and Territorial inspection personnel. | Cornell University | ORA Patricia L. Alcock Director, Division of Human Resource Development 301-796-4299 | 2015-12-18 | 2020-12-18 | |
| 225-16-014 | Promote scientific capital, training, research, training, and research expertise. Information sharing in regulatory science research, training, sabbaticals, postdoctoral, recruitment opportunities, fellowships, and student internships. | Rutgers University | ORA Paula Davy (718) 340-7942 Nazmul Hassan (718) 62-5707 | 2016-01-26 | 2026-01-26 | 2021-04-14 |
| 225-16-021 | Establishes terms for collaboration through a variety of programs, e.g., research, graduate student training, and exchange of scientists, exchange of staff, sabbaticals, post-doctoral fellowships, and student interns. | Worcester Polytechnic Institute | CDER Gerald J. Dal Pan, MD, MHS, CDER 301-796-2380 | 2016-08-25 | Indefinite | |
| 225-16-023 | Promote share interests in collaborative education and research. | Virginia Commonwealth University | Padmaja Mummaneni, Ph.D. 301-796-2027 | 2016-08-16 | 2027-11-08 | 2022-11-08 |
| 225-16-030 | To facilitate existing and new mutually agreed upon programs and activities to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | The University of Alabama’s School of Medicine, Department of Neurology | CDER Padmaja Mummaneni, Ph.D. 10902 New Hampshire Avenue, White Oak Building 51 Silver Spring, MD (301) 796-2027 | 2016-12-06 | 2021-12-06 | |
| 225-17-002 | Shared interests in promoting scientific progress through exchange of scientific capital in Clinical Pharmacology Training and Research Programs. Replaced MOU 225-11-0006. | University of California San Francisco | CDER Padmaja Mummaneni, 301-796-2027 | 2016-10-9 | 2021-10-08 | |
| 225-17-010 | This MOU establishes the terms for collaboration between FDA and HCV-TARGET to promote shared interests, which can be pursued through a variety of programs including collaborative research. | HCV-TARGET, the University of Florida, and the University of North Carolina at Chapel Hill | CDER Poonam Mishra, M.D., MPH Division Director (Safety) Division of Antiviral Products Office of New Drugs | 2017-02-16 | 2020-02-16 | |
| 225-17-017 | FDA and GUMC share interests In promoting scientific progress through the exchange of scientific capital in the diverse disciplines that directly and Indirectly affect human and animal health and medicine. | Georgetown University Medical Center | Khaled Bouri, Ph.D. Office of Regulatory Science and Innovation, Office of the Chief Scientist 301-796-8476 | 2017-06-09 | 2022-06-09 | |
| 225-17-024 | To facilitate existing and new mutually agreed upon programs and activities and establish the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | University of Washington School of Pharmacy | CDER Padmaja Mummaneni, PhD (301) 796-2027 | 2017-09-26 | 2022-09-26- | |
| 225-17-026 | Promote scientific progress through exchange of scientific capital to enhance the assessment of safety and efficacy of FDA-regulated products through joint educational and training fellowship programs. | Duke University | CDER | 2017-08-03- | 2022-08-02 | |
| 225-17-032 | This MOU establishes terms for collaboration to promote shared interests, which may be pursued through a variety of programs including collaborative education and research. | University of Utah | CDER Padmaja Mummaneni 10903 New Hampshire Avenue FDA White Oak Building 51, Room 2164 Silver Spring, MD 20993-0002 Telephone Number: 301-796-2027 | 2017-10-18 | 2022-10-18 | |
| 225-17-033 | This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | University of North Carolina at Chapel Hill | CDER Scott Goldie, Ph.D. 10903 New Hampshire Avenue Building 21 Room 3557 Silver Spring, MD 20993 (301) 796-2055 | 2017-09-14 | Indefinite | |
| 225-17-034 | The collaborative framework this MOU provides will facilitate existing and new mutually agreed upon programs and activities and establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | Stanford University School of Medicine, Department of Bioengineering | CDER Padmaja Mummaneni, PhD 10903 New Hampshire Avenue White Oak Building 51, Room 2164 Silver Spring, MD 20993-0002 (301) 796-2027 | 2017-10-06 | 2022-10-06 | |
| 225-17-035 | The parties want to collaborate on biomedical engineering projects of importance to the regulatory science priorities at CDRH. | Zhang Bioengineering Laboratory, Clemson University | CDRH Edward Margerrison, Ph.D., Director Office of Science and Engineering Laboratories Edward.Margerrison@fda.hhs.gov | 2017-09-15 | 2022-09-15 | |
| 225-17-036 | This MOU and the collaborative framework it provides will facilitate existing and new mutually agreed upon programs and activities, consortia and consensus development between the parties and establishes the terms for collaboration to promote shared interests. | Rutgers School of Health Professions | CDER Padmaja Mummaneni, Ph.D. Consumer Safety Officer 10903 New Hampshire Avenue White Oak Building 51, Room 2164 Silver Spring, MD 20993 (301) 796-2027 | 2017-10-16 | 2027-10-16 | 2023-05-19 |
| 225-17-037 | This MOU establishes the terms for collaboration to promote FDA and University of Pittsburgh’s shared interests, which can be pursued through a variety of programs. | University of Pittsburgh | CDER Padmaja Mummaneni, PhD (301) 796-2027 | 2018-01-18 | 2028-01-18 | 2023-05-15 |
| 225-18-001 | This MOU establishes the terms for collaboration to promote shared interests, which can be pursued through a variety of programs including collaborative education and research. | Vanderbilt University Medical Center (VUMC) | CDER Scott N. Goldie, Ph.D. Special Assistant for the Office of Biostatistics 10903 New Hampshire Avenue, Building 21 Room 3577 Silver Spring, MD 20993 | 2017-10-30 | Indefinite | |
| 225-18-004 | Establishes terms of collaboration between FDA and UMBC to support collaboration on specific projects related to biotechnology process validation, but can serve as a basis for future collaboration in other areas. | University of Maryland, Baltimore County | CDER Dr. Kurt Brorson (301) 796-2193 | 2003-07-25 | Indefinite | |
| 225-18-013 | Establishes a framework for this collaboration to enhance mutual cybersecurity and technology related interactions in education and research. | Montgomery College | Office of the Chief Information Officer Craig Taylor 301-796-8696 | 2018-03-28 | Indefinite | |
| 225-18-015 | Promote shared interests in various science-based academic initiatives, fellowships, internships, sabbaticals, research and scientific education. | Yale University | Office of Minority Health CAPT Richardae Araojo 301-796-1152 | 2018-03-28 | Indefinite | |
| 225-18-016 | Shared interests in promoting scientific progress through exchange of scientific capital in public health, epidemiology and research. | State University of New York at Buffalo | Office of Minority Health/OC Yeruk (Lily) Mulugeta 301-796-3162 | 2018-05-14 | 2023-05-13 | |
| 225-18-021 | Promotes scientific progress through exchange of scientific capital in clinical pharmacy and pharmacology training, research programs, clinical research in pharmacotherapy, biopharmaceutics, clinical pharmacology and translational science. | University of Georgia | CDER | 2018-08-28 | 2028-08-24 | 2023-10-03 |
| 225-18-029 | Collaborate on biomedical engineering projects of importance to the regulatory science priorities at CDRH. The parties have an interest in better understanding the bioengineering performance of many regulated medical and surgical devices. | University of Kentucky | CDRH Edward Margerrison, Ph.D. | 2018-09-18 | 2023-09-18 | |
| 225-19-003 | The purpose of MOU 225-19-003 is to establish a framework for collaborative educational, research and training opportunities. The joint efforts will be undertaken to develop collaborative research and training programs as permitted under appropriate statutory authority. | Massachusetts Institute of Technology | OC Sean Khozin, MD, MPH | 2019-01-30 | 2024-01-30 | |
| 225-20-015 | The Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), the American Association for Cancer Research (AACR), Oncology Nursing Society (ONS) and Hematology/Oncology Pharmacy Association (HOPA) agree to collaborate in Project Livin’ Label, a new educational initiative aimed at increasing awareness of recent FDA oncology drug approvals and understanding of the associated drug product label. The FDA, AACR, ONS and HOPA share interests in promoting scientific progress through exchange of scientific capital in oncology education, collaborative learning, and research. All institutions foresee benefits from collaborating in this new educational initiative focused on regulatory policy. This Memorandum of Understanding (MOU) establishes the terms for the collaboration for Project Livin’ Label and provides a basis for other related efforts to promote these shared, mutual interests in collaborative education and learning. | American Association for Cancer Research (AACR), Oncology Nursing Society (ONS) and Hematology/Oncology Pharmacy Association (HOPA) | Oncology Center of Excellence Laura B. Wisch Program Manager for Education 10903 New Hampshire Ave, WO 22/2135 Silver Spring, MD 20993 Laura.Wisch@fda.hhs.gov 301-538-6580 | 2022-05-03 | 2027-05-03 |
Sub-Topic Paragraphs